Patents by Inventor Issei Tsukamoto

Issei Tsukamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9562044
    Abstract: Thiazole derivatives having pyrazine-2-carbonylamino substituted at the 2-position of the following formula (I): are excellent muscarinic M3 receptor positive allosteric modulators, and are useful for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor. The 2-acylaminothiazole derivatives and salts thereof can be used for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, for example, voiding dysfunctions such as underactive bladder.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: February 7, 2017
    Assignee: Astellas Pharma Inc.
    Inventors: Taisuke Takahashi, Jun Maeda, Yusuke Inagaki, Kenji Negoro, Hiroaki Tanaka, Kazuhiro Yokoyama, Hajime Takamatsu, Takanori Koike, Issei Tsukamoto
  • Publication number: 20160002218
    Abstract: [Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, for example, voiding dysfunctions such as underactive bladder.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 7, 2016
    Applicant: Astellas Pharma Inc.
    Inventors: Taisuke TAKAHASHI, Jun MAEDA, Yusuke INAGAKI, Kenji NEGORO, Hiroaki TANAKA, Kazuhiro YOKOYAMA, Hajime TAKAMATSU, Takanori KOIKE, Issei TSUKAMOTO
  • Patent number: 8314240
    Abstract: [Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: November 20, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Issei Tsukamoto, Kazunori Kamijo, Koji Kato, Yuta Fukuda, Hidenori Azami
  • Publication number: 20110201616
    Abstract: [Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
    Type: Application
    Filed: June 22, 2009
    Publication date: August 18, 2011
    Applicant: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Issei Tsukamoto, Kazunori Kamijo, Koji Kato, Yuta Fukuda, Hidenori Azami
  • Patent number: 7973078
    Abstract: A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: July 5, 2011
    Assignee: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Susumu Toda, Issei Tsukamoto, Yuta Fukuda, Ryutaro Wakayama, Kazuki Ono, Toru Watanabe, Hidenori Azami
  • Patent number: 7879878
    Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: February 1, 2011
    Assignee: Astellas Pharma Inc.
    Inventors: Susumu Watanuki, Yuji Koga, Hiroyuki Moritomo, Issei Tsukamoto, Daisuke Kaga, Takao Okuda, Fukushi Hirayama, Yumiko Moritani, Jun Takasaki
  • Patent number: 7807664
    Abstract: A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: October 5, 2010
    Assignee: Astella Pharma Inc.
    Inventors: Hiroyuki Koshio, Issei Tsukamoto, Akio Kakefuda, Seijiro Akamatsu, Chikashi Saitoh
  • Publication number: 20090312328
    Abstract: [Object] A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom. [Means for Solution] It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
    Type: Application
    Filed: August 9, 2007
    Publication date: December 17, 2009
    Applicant: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Susumu Toda, Issei Tsukamoto, Yuta Fukuda, Ryutaro Wakayama, Kazuki Ono, Toru Watanabe, Hidenori Azami
  • Publication number: 20090124617
    Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
    Type: Application
    Filed: December 31, 2008
    Publication date: May 14, 2009
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Susumu WATANUKI, Yuji KOGA, Hiroyuki MORITOMO, Issei TSUKAMOTO, Daisuke KAGA, Takao OKUDA, Fukushi HIRAYAMA, Yumiko MORITANI, Jun TAKASAKI
  • Patent number: 7488739
    Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: February 10, 2009
    Assignee: Astellas Pharma Inc.
    Inventors: Susumu Watanuki, Yuji Koga, Hiroyuki Moritomo, Issei Tsukamoto, Daisuke Kaga, Takao Okuda, Fukushi Hirayama, Yumiko Moritani, Jun Takasaki
  • Publication number: 20070167429
    Abstract: A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided.
    Type: Application
    Filed: November 14, 2006
    Publication date: July 19, 2007
    Inventors: Hiroyuki Koshio, Issei Tsukamoto, Akio Kakefuda, Seijiro Akamatsu, Chikashi Saitoh
  • Patent number: 7196080
    Abstract: The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (wherein R1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like, R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like, R5: hydrogen, a lower alkyl, a lower alkoxycarbonyl, or the like, and n: 0 or 1).
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: March 27, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Masahiro Iwata, Noriyuki Kawano, Hiroyuki Kaizawa, Tomofumi Takuwa, Issei Tsukamoto, Ryushi Seo, Kiyoshi Yahiro, Miki Kobayashi, Makoto Takeuchi
  • Patent number: 7183271
    Abstract: A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: February 27, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Hiroyuki Koshio, Issei Tsukamoto, Akio Kakefuda, Seijiro Akamatsu, Chikashi Saitoh
  • Patent number: 7173033
    Abstract: As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: February 6, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Susumu Igarashi, Ryo Naito, Yoshinori Okamoto, Noriyuki Kawano, Issei Tsukamoto, Ippei Sato, Makoto Takeuchi, Hiroyuki Kanoh, Masato Kobori
  • Patent number: 7169772
    Abstract: 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin V2 activity and are useful for a drug for the treatment of central diabetes insipidus and/or nocturia.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: January 30, 2007
    Assignee: Astellas Pharma Inc.
    Inventors: Hiroyuki Koshio, Issei Tsukamoto, Takahiro Kuramochi, Seijiro Akamatsu, Chikashi Saitoh
  • Publication number: 20060148806
    Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
    Type: Application
    Filed: July 22, 2004
    Publication date: July 6, 2006
    Inventors: Susumu Watanuki, Yuji Koga, Hiroyuki Moritomo, Issei Tsukamoto, Daisuke Kaga, Takao Okuda, Fukushi Hirayama, Yumiko Moritani, Jun Takasaki
  • Publication number: 20060122170
    Abstract: A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided.
    Type: Application
    Filed: April 26, 2004
    Publication date: June 8, 2006
    Applicant: ASTELLA PHARMA INC.
    Inventors: Hiroyuki Koshio, Issei Tsukamoto, Akio Kakefuda, Seijiro Akamatsu, Chikashi Saitoh
  • Publication number: 20050261297
    Abstract: As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.
    Type: Application
    Filed: July 28, 2005
    Publication date: November 24, 2005
    Inventors: Susumu Igarashi, Ryo Naito, Yoshinori Okamoto, Noriyuki Kawano, Issei Tsukamoto, Ippei Sato, Makoto Takeuchi, Hiroyuki Kanoh, Masato Kobori
  • Publication number: 20050096322
    Abstract: As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.
    Type: Application
    Filed: February 27, 2003
    Publication date: May 5, 2005
    Inventors: Susumu Igarashi, Ryo Naito, Yoshinori Okamoto, Noriyuki Kawano, Issei Tsukamoto, Ippei Sato, Makoto Takeuchi, Hiroyuki Kanoh, Masato Kobori
  • Publication number: 20050004103
    Abstract: 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin V2 activity and are useful for a drug for the treatment of central diabetes insipidus and/or nocturia.
    Type: Application
    Filed: November 13, 2002
    Publication date: January 6, 2005
    Inventors: Hiroyuki Koshio, Issei Tsukamoto, Takahiro Kuramochi, Seijiro Akamatsu, Chikashi Saitoh